GRI Bio, Inc. (GRI)

In December 2025, GRI Bio announced an $8.0 million public offering. Positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis was announced in December 2025 and January 2026. A reverse stock split was announced in January 2026. GRI Bio secured a new U.S. composition of matter patent in January 2026. The company regained Nasdaq compliance in January and March 2026. Full-year 2025 financial results were reiterated in February 2026, reporting $8.2 million in cash and an additional $6.5 million raised in January 2026. The stock price has decreased significantly over the last 12 months and in the past month.

As a clinical-stage biopharmaceutical company, GRI Bio, Inc. does not experience traditional demand seasonality for its products and services, as its primary products are not yet commercially available. Demand for its pipeline products will be driven by clinical trial outcomes, regulatory approvals, and the prevalence of the diseases they aim to treat.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune disorders, operating within the Pharmaceuticals & Biotech sector. Its pipeline focuses on modulating Natural Killer T (NKT) cells, with major product candidates including GRI-0621 (Phase IIa for fibrotic lung diseases), GRI-0803 (preclinical for autoimmune disorders), GRI-0124 (pre-clinical development for primary sclerosing cholangitis), GRI-0729, ADAIR and ADMIR (in development for the treatment of attention-deficit/hyperactivity disorder). The company also possesses a library of over 500 compounds.

GRI Bio, Inc. is headquartered in La Jolla, California, United States, and its operations and focus for developing and commercializing therapies are primarily within the United States.

GRI Bio's brand reputation has been influenced by positive clinical data and intellectual property developments, alongside stock market challenges. Positive events include announcing positive Phase 2a topline data for GRI-0621 and securing a new U.S. composition of matter patent. Regaining compliance with Nasdaq listing requirements also helped. However, the company's reputation has been challenged by a substantial decrease in stock price and analyst ratings citing concerns about weak financial performance.

GRI Bio, Inc. has 8 institutional owners and shareholders, holding 33.95% of the stock, including DRW Securities, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Tower Research Capital LLC (TRC), BlackRock, Inc., and Bank Of America Corp /de/. Individual investors (insiders) hold 8.73% of the stock.